title: Treatment of the primary hyperoxalurias: a new chapter.
abstract: Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.
authors.affiliation: Mayo Clinic Hyperoxaluria Center, Rochester, Minnesota 55905, USA. milliner.dawn@mayo.edu
authors.forename: D
authors.initials: D
authors.lastname: Milliner
mesh_terms: D000284:Administration, Oral; D000818:Animals; D006801:Humans; D006960:Hyperoxaluria, Primary / Q000150:complications / Q000628:therapy*; D007674:Kidney Diseases / Q000150:complications; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D010070:Oxalates / Q000097:blood / Q000378:metabolism / Q000652:urine; D020624:Oxalobacter formigenes / Q000378:metabolism; D051381:Rats; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010070:Oxalates